Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16601244rdf:typepubmed:Citationlld:pubmed
pubmed-article:16601244lifeskim:mentionsumls-concept:C0023434lld:lifeskim
pubmed-article:16601244lifeskim:mentionsumls-concept:C1171362lld:lifeskim
pubmed-article:16601244lifeskim:mentionsumls-concept:C0246976lld:lifeskim
pubmed-article:16601244lifeskim:mentionsumls-concept:C2826293lld:lifeskim
pubmed-article:16601244pubmed:issue3lld:pubmed
pubmed-article:16601244pubmed:dateCreated2006-7-24lld:pubmed
pubmed-article:16601244pubmed:abstractTextThe clinical course of B-cell chronic lymphocytic leukemia (B-CLL) is variable, and novel biologic parameters need to be added to the clinical staging systems to predict an indolent or aggressive outcome. We investigated the 70-kDa zeta-associated protein (ZAP-70), CD38, soluble CD23 (sCD23), and cytogenetics in 289 patients with B-CLL. Both a shorter progression-free survival (PFS) and overall survival (OS) were observed in ZAP-70(+) (P < .001), in CD38(+) (P < .001) and in sCD23(+) patients (P < .001 and P = .013, respectively). ZAP-70(+)CD38(+) or ZAP-70(+) patients with an unmutated IgV(H) status showed both a shorter PFS (P < .001) and OS (P < .001 and P < .001, respectively) as compared with ZAP-70(-)/CD38(-) or ZAP-70(-) patients with mutated IgV(H) genes. Discordant patients showed an intermediate outcome. Note, ZAP-70(+) patients even if CD38(-) or mutated showed a shorter PFS, whereas ZAP-70(-) patients even if CD38(+) or unmutated had a longer PFS. Furthermore, ZAP-70 positivity was associated with a shorter PFS both within normal karyotype (P < .001) and within the poor-risk cytogenetic subset (P = .02). The predictive value of ZAP-70 expression was confirmed in multivariate analysis. Thus, ZAP-70 protein determined by flow cytometry improves the prognostic significance of cytogenetics and appears to be a better predictor of outcomes than IgV(H) gene mutational status. On this line, we recommend and are also interested in conducting a prospective randomized trial of early intervention versus observation for ZAP-70(+) patients.lld:pubmed
pubmed-article:16601244pubmed:languageenglld:pubmed
pubmed-article:16601244pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16601244pubmed:citationSubsetAIMlld:pubmed
pubmed-article:16601244pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16601244pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16601244pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16601244pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16601244pubmed:statusMEDLINElld:pubmed
pubmed-article:16601244pubmed:monthAuglld:pubmed
pubmed-article:16601244pubmed:issn0006-4971lld:pubmed
pubmed-article:16601244pubmed:authorpubmed-author:Lo...lld:pubmed
pubmed-article:16601244pubmed:authorpubmed-author:GatteiValterVlld:pubmed
pubmed-article:16601244pubmed:authorpubmed-author:AmadoriSergio...lld:pubmed
pubmed-article:16601244pubmed:authorpubmed-author:DeganMassimoMlld:pubmed
pubmed-article:16601244pubmed:authorpubmed-author:VendittiAdria...lld:pubmed
pubmed-article:16601244pubmed:authorpubmed-author:BuccisanoFran...lld:pubmed
pubmed-article:16601244pubmed:authorpubmed-author:Del...lld:pubmed
pubmed-article:16601244pubmed:authorpubmed-author:MaurilloLucaLlld:pubmed
pubmed-article:16601244pubmed:authorpubmed-author:PanettaPaolaPlld:pubmed
pubmed-article:16601244pubmed:authorpubmed-author:CantonettiMar...lld:pubmed
pubmed-article:16601244pubmed:authorpubmed-author:BrunoAntonioAlld:pubmed
pubmed-article:16601244pubmed:authorpubmed-author:Del...lld:pubmed
pubmed-article:16601244pubmed:authorpubmed-author:de...lld:pubmed
pubmed-article:16601244pubmed:authorpubmed-author:Del...lld:pubmed
pubmed-article:16601244pubmed:authorpubmed-author:MazzoneCarlaClld:pubmed
pubmed-article:16601244pubmed:authorpubmed-author:SuppoGiovanna...lld:pubmed
pubmed-article:16601244pubmed:authorpubmed-author:NiscolaPasqua...lld:pubmed
pubmed-article:16601244pubmed:authorpubmed-author:BombenRiccard...lld:pubmed
pubmed-article:16601244pubmed:authorpubmed-author:ZucchettoAnto...lld:pubmed
pubmed-article:16601244pubmed:authorpubmed-author:OttavianiLici...lld:pubmed
pubmed-article:16601244pubmed:authorpubmed-author:MariniRitaRlld:pubmed
pubmed-article:16601244pubmed:authorpubmed-author:ConsalvoMaria...lld:pubmed
pubmed-article:16601244pubmed:issnTypePrintlld:pubmed
pubmed-article:16601244pubmed:day1lld:pubmed
pubmed-article:16601244pubmed:volume108lld:pubmed
pubmed-article:16601244pubmed:ownerNLMlld:pubmed
pubmed-article:16601244pubmed:authorsCompleteYlld:pubmed
pubmed-article:16601244pubmed:pagination853-61lld:pubmed
pubmed-article:16601244pubmed:dateRevised2009-11-19lld:pubmed
pubmed-article:16601244pubmed:meshHeadingpubmed-meshheading:16601244...lld:pubmed
pubmed-article:16601244pubmed:meshHeadingpubmed-meshheading:16601244...lld:pubmed
pubmed-article:16601244pubmed:meshHeadingpubmed-meshheading:16601244...lld:pubmed
pubmed-article:16601244pubmed:meshHeadingpubmed-meshheading:16601244...lld:pubmed
pubmed-article:16601244pubmed:meshHeadingpubmed-meshheading:16601244...lld:pubmed
pubmed-article:16601244pubmed:meshHeadingpubmed-meshheading:16601244...lld:pubmed
pubmed-article:16601244pubmed:meshHeadingpubmed-meshheading:16601244...lld:pubmed
pubmed-article:16601244pubmed:meshHeadingpubmed-meshheading:16601244...lld:pubmed
pubmed-article:16601244pubmed:meshHeadingpubmed-meshheading:16601244...lld:pubmed
pubmed-article:16601244pubmed:meshHeadingpubmed-meshheading:16601244...lld:pubmed
pubmed-article:16601244pubmed:meshHeadingpubmed-meshheading:16601244...lld:pubmed
pubmed-article:16601244pubmed:meshHeadingpubmed-meshheading:16601244...lld:pubmed
pubmed-article:16601244pubmed:meshHeadingpubmed-meshheading:16601244...lld:pubmed
pubmed-article:16601244pubmed:meshHeadingpubmed-meshheading:16601244...lld:pubmed
pubmed-article:16601244pubmed:meshHeadingpubmed-meshheading:16601244...lld:pubmed
pubmed-article:16601244pubmed:meshHeadingpubmed-meshheading:16601244...lld:pubmed
pubmed-article:16601244pubmed:meshHeadingpubmed-meshheading:16601244...lld:pubmed
pubmed-article:16601244pubmed:meshHeadingpubmed-meshheading:16601244...lld:pubmed
pubmed-article:16601244pubmed:year2006lld:pubmed
pubmed-article:16601244pubmed:articleTitleClinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia.lld:pubmed
pubmed-article:16601244pubmed:affiliationCattedra di Ematologia, Università Tor Vergata, Ospedale S Eugenio, Via Fiume Giallo, 430 MA, 00144 Roma, Rome, Italy.lld:pubmed
pubmed-article:16601244pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16601244pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16601244lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16601244lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16601244lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16601244lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16601244lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16601244lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16601244lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16601244lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16601244lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16601244lld:pubmed